Resources

When asked in a survey, 77% got it wrong! In head-to-head trials of dipeptidyl peptidase 4 (DPP-4) inhibitors vs glucagon-like peptide 1 (GLP-1) receptor agonists, GLP-1 receptor agonists showed more favorable outcomes in all of the following areas except which one? A. Greater glycemic control B. Greater tolerability C. Greater weight loss D. Greater improvement in beta-cell function E. Greater reduction in postprandial triglycerides Were you able to get it right? Follow the link to find out!

Now that a new combination drug of a GLP-1 plus DPP-4 is approved, will you: 1. Recommend it for current patients 2. Wait until we have further information on its use 3. Not sure Follow the link to respond and see what your colleagues think.

A patient, 48 years of age, female, type 2 diabetes and obese, was referred to me for diabetes and weight management. Her first visit was 8 a.m., after fasting for 10 hours. Her A1c was 7.4%, BMI 37, BP 164/92, HR 92. The previous hcp had recorded she was recommended a low carb diet and the following medications: Metformin, 1,000mg twice daily; Byetta 10mcg sq twice daily. It was also written that she was non-compliant.

In part 3 of this Exclusive Interview, Blandine Lacroix talks about applying motivational interviewing in the patient/provider conversation around diabetes.

In this week's Homerun Slides, recognizing the role of Glycocalyx in microvascular and macrovascular dysfunction.

Type 1 beta cells succumb to autoimmunity, leaving significantly reduced beta-cell mass and lifelong dependence on insulin replacement therapy, while type 2 beta cells fail to secrete sufficient insulin to overcome prevailing insulin resistance.

In a new international clinical trial, it was shown that the drug liraglutide 3.0 mg may reduce diabetes risk by 80% in individuals with obesity and prediabetes.

Insulin resistance associated with high blood pressure and other risk factors.

Is the use of continuous glucose monitoring alone superior versus its use with the blood glucose monitoring?

Valsartan associated with reduction in new onset diabetes in patients with impaired glucose tolerance